The one-year returns have been solid for Starpharma Holdings (ASX:SPL) shareholders despite underlying losses increasing

Unless you borrow money to invest, the potential losses are limited. But if you pick the right business to buy shares in, you can make more than you can lose. For example, the Starpharma Holdings Limited (ASX:SPL) share price has soared 300% return in just a single year. It’s also good to see the share price up 223% over the last quarter. Unfortunately the longer term returns are not so good, with the stock falling 21% in the last three years.

After a strong gain in the past week, it’s worth seeing if longer term returns have been driven by improving fundamentals.

Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

Because Starpharma Holdings made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn’t make profits, we’d generally hope to see good revenue growth. That’s because it’s hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Starpharma Holdings actually shrunk its revenue over the last year, with a reduction of 40%. We’re a little surprised to see the share price pop 300% in the last year. This is a good example of how buyers can push up prices even before the fundamental metrics show much growth. Of course, it could be that the market expected this revenue drop.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

We’re pleased to report that Starpharma Holdings shareholders have received a total shareholder return of 300% over one year. Notably the five-year annualised TSR loss of 11% per year compares very unfavourably with the recent share price performance. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we’ve spotted 2 warning signs for Starpharma Holdings (of which 1 doesn’t sit too well with us!) you should know about.

But note: Starpharma Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.